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Abstract: A new series of chiral ferrocene derivatives containing 
both a hydroxyalkyl group and a thyminyl group on one 
cyclopentadienyl ring have been synthesised in order to probe 
structure activity relationships in cancer cell-line cytotoxicities. 
Stereoisomers of enantiomeric pairs of these so-called 
ferronucleosides have been studied and characterised by a 
combination of chiral analytical HPLC and single crystal X-Ray 
diffraction. Biological activity studies reveal that changing the 
length of the hydroxyalkyl group had marked effects on IC50 
values, with compounds having shorter arms that more closely 
resemble endogenous nucleosides exhibiting lower cytotoxicities. 
Lipophilicities and electrochemical properties of this compound 
series have been studied in order to rationalise these trends and 
indicate future directions of study. 
Introduction 
Nucleoside analogues are a class of compound which interfere 
with the processes of nucleic acid synthesis through the 
mimicking of endogenous substrates. The effectiveness of this 
class of molecules in treating cancer and various viral infections 
was established a few decades ago.[1],[2] The sugar unit in these 
drug molecules is frequently modified (e.g. in AZT or gemcitabine) 
or completely replaced (e.g. in abacovir and acyclovir). 
Fundamentally therefore, for conventional nucleoside mimics, the 
sugar unit may be viewed as a modifiable or replaceable linker 
between the active hydroxyl and nucleobase moieties (Figure 
1).[3] 
 
Due to its stability, ease of functionalisation and potential for novel 
modes of action through its redox properties, ferrocene has been 
at the centre of the now established field of bioorganometallic 
medicinal chemistry.[4] Complementing the mode of action of the 
parent compound, the anti-malarial ferroquine and the breast 
cancer drug candidate ferrocifen are the most well-known 
examples in which beneficial secondary mechanisms of action 
are conferred upon incorporation of the ferrocene moiety.[5] For 
various ferrocene derivatives, studies indicate that cancer cell 
cytotoxicity derives from oxidation to the ferrocenium ion, 
facilitating the generation of reactive-oxygen-species (ROS) 
which, in turn, inflict damage upon the genetic material, thereby 
inducing apoptosis.[5c],[6] 
 
Aiming to exploit such apposite biological properties and the 
potential for novel modes of action, we recently reported the 
promising anti-cancer activity of organometallic analogues of 
nucleosides in which the five-membered sugar ring is entirely 
replaced by a cyclopentadienyl unit in ferrocene.[7] Micro- and 
sub-micromolar activities against various cancer cell lines were 
observed for the thymine derivative 1-(S,Rp) (Figure 1) and its 
adenine counterpart containing both a hydroxyalkyl linker and a 
nucleobase. In order to establish the mode of action of these so-
called ferronucleosides, we have begun to explore the effect of 
structure and stereochemistry on cell cytotoxicity. As a starting 
point, we decided to synthesise enantiomers of two new thymine-
containing compounds in which the hydroxyalkyl linker length is 
reduced from three to two and one carbon atoms respectively. 
The results demonstrate how small structural changes to these 
ferronucleosides can have a marked effect on biological activity. 
Figure 1. The DNA nucleoside thymidine, a nucleoside analogue and 
structures of the ferronucleoside target compounds in this study. 
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The rationale for varying the linker length between the Cp ring and 
the hydroxyl group in these ferronucleoside compounds was as 
follows.  Firstly it was considered important to assess the effect 
on cell toxicity of lipophilicity. Secondly previous cancer cell line 
studies on mono-functionalised ferrocene derivatives had 
indicated that the length of an alkyl chain connected to the Cp ring 
had a marked affect on toxicity,[8] with a possible link to the redox 
potential of the ferrocene unit. Thirdly, in the spirit of making 
structural analogues of natural compounds, it was considered that 
a shorter linker length to the alcohol group would give compounds 
more closely resembling those of endogenous nucleosides. At the 
same time, it was also considered opportune to examine the effect 
of stereochemistry on cancer cell toxicities by synthesizing the 
enantiomers of these two new compounds. 
 
Conveniently, it was found that the two target compounds 2-(Sp) 
and 3-(Rp) could be made from one common synthon 8-(Rp), as 
was the case for their opposite enantiomers. The synthesis of 8-
(Rp) is outlined in Scheme 1. The chirally pure (S,Rp)-2-α-O-
acetoxyethyl-1-iodo-ferrocene 4-(Rp) was made accordingly to 
our previously published method[7a] and then heated in the 
presence of LiBr to give the corresponding 1-iodo-2-
vinylferrocene 5-(Rp). A hydroboration-oxidation reaction gave 
alcohol 6-(Rp) which, after benzyl protection, was treated with n-
BuLi to affect a halogen-metal exchange before quenching with 
DMF, to give the desired aldehyde 8-(Rp). 
 
Scheme 1. Synthesis of synthon 8-(Rp). 
Compound 2-(Sp) was synthesised (Scheme 2) from 8-(Rp) by 
converting the aldehyde to a vinyl group using the Wittig reaction, 
before hydroboration-oxidation placed a hydroxyl group at the β-
position. This compound was then reacted with N3-benzoyl 
thymine using the Mitsunobu reaction before removal of the 
benzyl group by hydrogenolysis and deprotection of the 
nucleobase gave the desired target compound. 
 
 
 
 
Scheme 2. Synthesis of 2-(Sp) from chiral synthon 8-(Rp). 
 
Scheme 3. Synthesis of 3-(Rp) from chiral synthon 8-(Rp). 
The route towards the methyl linker target 3-(Rp) from the same 
synthon 8-(Rp) proceeded by protecting the aldehyde as a cyclic 
acetal using 2,2-dimethylpropane-1,3-diol (Scheme 3). Benzyl 
deprotection was again affected by hydrogenolysis, and the 
corresponding free alcohol employed in a Mitsunobu reaction with 
N3-benzoyl thymine. The acetal group was removed using PTSA 
in wet THF and the regenerated aldehyde reduced to the 
corresponding alcohol using NaBH4. Finally, the nucleobase was 
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deprotected using ammonia in methanol to give the target 
compound. 
 
Compounds 2-(Rp) and 3-(Sp) were synthesised in an identical 
fashion starting from the opposite enantiomer 8-(Sp). The 
enantiopurities of these four planar chiral targets were assessed 
by analytical chiral HPLC, giving values as follows: 2-(Rp), 97%; 
2-(Sp); 97%; 3-(Rp), 95%; 3-(Sp), 92%. Fortunately, crystals of all 
four compounds, grown by the slow evaporation of concentrated 
solutions in ethyl acetate and chloroform for enantiomers of 2 and 
3 respectively, were found to be suitable for X-Ray diffraction. The 
structures of the Rp enantiomers of 2 and 3 are depicted in Figures 
2 and 3 respectively, with those for the Sp enantiomers presented 
in the supplementary information. 
 
 
 
 
 
Figure 2. Crystal structure of 2-(Rp) with ellipsoids drawn at the 50% 
probability level. The cyclopentadienyl ring C(15)-C(19) / C(15’)-C(19’) and the 
group C(20), C(21), O(21) / C(20’), C(21’), O(21’) are both disordered over two 
positions, for clarity only the major positions are shown. 
 
Figure 3. Crystal structure of 3-(Rp) with ellipsoids drawn at the 50% 
probability level. The structure contains two crystallographically-independent 
molecules of which only one is shown. 
The Rp isomers of compounds 1, 2 and 3 were characterised with 
cyclic voltammetry (CV) in dry acetonitrile (Fig. 4) and the half-
wave potentials, E1/2, were determined from the peak positions 
with respect to decamethylferrocene (dmfc) as the internal 
reference of (Table 1). In each case, the ratio of the peak heights 
of the oxidation and reduction waves was close to unity, plots of 
peak current vs the square root of the scan rate were linear and 
the peak separations were as measured for dmfc (ca. 65–70 mV), 
indicating reversible one-electron redox behaviour for all three 
compounds (see supplementary information). It is clear that as 
the hydroxyalkyl linker length increases, the E1/2 value becomes 
more negative, indicating the progressive stabilisation of the 
ferrocenium ion. This is consistent with the longer alkyl linker 
stabilising the ferrocenium cation through increased positive 
inductive effects, as found previously for related compounds.[9] 
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Figure 4. Cyclic voltammograms of 1-(S,Rp) at various scan rates wrt 
decamethylferrocene. Concentration 1.0 mM with 0.1 M TBAPF6 in dry 
acetonitrile at RT. 
Previous studies[7] indicated that 1-(S,Rp) was active in three 
different human cancer cell lines. For this study, it was decided to 
probe its activity further in a human osteosarcoma (HOS) cell line 
and compare these with its enantiomer as well as with compounds 
2, 3 and the established anticancer drug cisplatin. HOS cells were 
exposed to various concentrations of test agent for four days and 
the cell number assessed using the crystal violet assay. The 
resulting IC50 values calculated from the inhibition curves are 
presented in Table 1. In general agreement with our previous 
studies on other cell lines,[7] 1-(S,Rp) with its three-carbon spacer 
displays low micromolar activity with an IC50 value of 4.4 ȝM. 
However a clear trend between the length of the hydroxyalkyl arm 
and the IC50 values was observed; compounds 2-(Rp) and 2-(Sp) 
with one fewer carbon were found to be approximately one order 
of magnitude less active than 1-(S,Rp), with IC50 values of 58.4 
and 57.8 ȝM respectively. Furthermore, 3-(Rp) and 3-(Sp) with just 
a methylene spacer, display lower cytotoxicities still with IC50 
values of 73.1 and 86.0 ȝM respectively. Differences in biological 
activity between the enantiomers for compounds 2 and 3 do not 
appear to be significant.  
Figure 5. Inhibition of HOS cells after four days incubation with each 
compound. The results represent the mean of at least three independent 
experiments ± SEM (n=3).    
 
    
 
 
 
 
 
Table 1. IC50, E1/2 and CLogP values for various stereoisomers of 
ferronucleosides 1, 2 and 3. 
Compound IC50 (ȝM)[a] E1/2 (mV)[b] CLogP[c] 
1-(S,Rp) 4.4 424 + 0.96 
2-(Rp) 58.4 467 + 0.03 
2-(Sp) 57.8 nd + 0.03 
3-(Rp) 73.1 518 – 0.05 
3-(Sp) 86.0 nd – 0.05 
Cisplatin 0.31 – nd 
[a] 50% inhibitory concentration, or compound concentration required to 
inhibit tumor cell proliferation by 50%, after 4 days incubation. All 
compounds [b] versus decamethylferrocene, measured at 1 mM 
concentration in 0.1 M TBAPF6 in dry acetonitrile. Confidence limit ± 5mV [c] 
Calculated using ChemBioDraw Ultra 13.0.[9a] nd = not determined 
(enantiomers would have identical data). 
 
As previously reported for a series of simple ferrocenyl 
compounds,[8] cell cytotoxicity is inversely related to the E1/2 value, 
suggesting that biological activity could be linked to the 
thermodynamic favourability of oxidation to the ferrocenium ion 
(E1/2: 1 < 2 < 3). However another important consideration is 
lipophilicity, which would also be expected to change as a function 
of the alkyl linker length. An increase in drug activity with higher 
lipophilicity can be explained by better diffusivity across cellular 
and nuclear membranes, thus producing much higher 
concentrations at the site of action. Drug lipophilicities are 
normally quantified through octanol–water partition coefficients 
(LogP values). Predicted coefficients (as CLogP) values, 
calculated using a method previously applied to ferrocene 
compounds,[9a] are also displayed in Table 1. As expected, the 
trend in these values (CLogP: 1 > 2 > 3) also correlates with 
hydroxyalkyl arm linker length. Interestingly, lipophilicity has been 
previously shown to be linearly correlated with oxidation 
potentials for a series of structurally related ferrocene 
derivatives.[9a] 
Conclusions 
Enantiomers of two new structural variations within a series of 
ferronucleosides, in which the hydroxyalkyl linker length has been 
shortened to two and one carbon atoms respectively, have been 
successfully synthesised and characterised. The biological data 
for this novel ferrocene series demonstrate a marked structure 
activity relationship, with their cytotoxicities becoming 
progressively lower as their structure tends towards that of an 
endogenous nucleoside (i.e. thymidine). A consideration of their 
respective E1/2 and CLogP values therefore indicates that the 
thermodynamic ease of oxidation to the ferrocenium ion and 
lipophilicity may in fact be more central to their biological activity 
than their structural conformity to the traditional nucleoside 
analogue pharmacophore. Further studies are now underway to 
establish whether the mechanism of action of 1-(S,Rp) and related 
compounds resembles that of a typical nucleoside analogue, or a 
new pathway in which the structure and properties of the 
ferrocene unit play a prominent and distinct role. 
Experimental Section 
Synthesis 
 
(Rp)-1-iodo-2-vinyl-ferrocene (5-(Rp)) 
(S,Rp)-2-α-O-acetoxyethyl-1-iodo-ferrocene (4-(S,Rp)) (4.30 g, 10.81 
mmol, 1.0 eq.) was dissolved in dry DMF (20 ml), LiBr (14.0 g, 162 mmol, 
15.0 eq.) was added and the resulting mixture heated at 85 °C for 1 hr with 
stirring. The reaction was quenched by addition of sat. Na2S2O3 solution, 
extracted with DCM, washed with water (2 x 100 ml), dried over MgSO4 
and the solvent removed in vacuo. The crude product was purified by flash 
column chromatography on neutralised (Et3N) silica gel using an eluent of 
hexane. The solvent was removed in vacuo to give the title compound as 
a dark orange oil (3.40 g, 10.09 mmol, 93 %). 1H NMR (300 MHz, CDCl3) 
δ 6.58 (dd, J = 17.5, 10.9 Hz, 1H (CH=CH2), 5.50 (dd, J = 17.5, 1.4 Hz, 1H 
(CH2=CH)), 5.22 (dd, J = 10.9, 1.4 Hz, 1H (CH2=CH)), 4.55 (dd, J = 2.6, 
1.4 Hz, 1H (Fc CH)), 4.53 (dd, J = 2.6, 1.4 Hz, 1H (Fc CH)), 4.34 (dd, J = 
2.6, 2.6 Hz, 1H (Fc CH)), 4.14 (s, 5H (cp CH)). 13C NMR (400 MHz, CDCl3) 
δ 134.21 (CH=CH2), 113.27 (CH2=CH), 84.19 (Fc C–CH), 75.33 (Fc CH), 
72.35 (cp CH), 69.54 (Fc CH), 63.80 (Fc CH), 45.01 (Fc C–I). Ȟmax/cm-1 = 
3087 (Fc CH), 1628 (C=C). HRMS (ESI-TOF) m/z: [M]+ Calcd for 
C12H11FeI 337.9255; Found 337.9258. 
Producing matching 1H and 13C NMR spectra, (Sp)-1-iodo-2-vinyl-
ferrocene (5-(Sp)) (2.32 g, 6.85 mmol 88 %) was prepared according to the 
same procedure from (R,Sp)-2-α-O-acetoxyethyl-1-iodo-ferrocene (4-
(R,Sp)) (3.09 g, 7.77 mmol). 
(Rp)-2-β-hydroxyethyl-1-iodo-ferrocene (6-(Rp)) 
(Rp)-1-iodo-2-vinyl-ferrocene (5-(Rp)) (3.40 g, 10.09 mmol, 1.0 eq) was 
dissolved in dry THF (30 ml) in a Schlenk tube under an atmosphere of 
argon and cooled to 0 °C in an ice bath. BH3•THF (1M in THF) (8.87 ml, 
8.87 mmol, 1.5 eq.) was added dropwise and stirring continued at 0 °C for 
1 hr then the solution was warmed to room temperature and stirring 
continued for another 1.5 hrs. EtOH (8.87 ml) was carefully added and 
stirring continued for 5 min, followed by the dropwise addition of NaOH 
(3M in H2O) (8.87 ml) and a further 10 min of stirring. H2O2 (30 % in H2O) 
(16 ml) was then added slowly and stirring continued for 30 min. The 
reaction was extracted with Et2O, washed with water (2 x 100 ml) and dried 
over MgSO4. The solvent was removed in vacuo and the crude product 
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purified by flash column chromatography on silica gel using a gradient 
eluent system of 5 → 10 % EtOAc in hexane. The solvent was removed in 
vacuo to give the title compound as a yellow oil (3.34 g, 9.38 mmol, 93 %). 
1H NMR (300 MHz, CDCl3) δ 4.41 (dd, J = 2.5, 1.4 Hz, 1H (Fc CH)), 4.21 
(dd, J = 2.5, 1.4 Hz, 1H (Fc CH)), 4.18 (dd, J = 2.5, 2.5 Hz, 1H (Fc CH)), 
4.12 (s, 5H (cp CH)), 3.85 – 3.62 (m, 2H (CH2OH)), 2.83 – 2.55 (m, 2H 
(CH2CH2OH)), 1.61 (s, 2H (OH)). 13C NMR (400 MHz, CDCl3) δ 86.22 (Fc 
C–CH2), 74.49 (Fc CH), 71.73 (cp CH), 68.59 (Fc CH), 67.71 (Fc CH), 
63.00 (CH2OH), 45.51 (Fc C–I), 33.48 (CH2CH2OH). Ȟmax/cm-1 = 3303 (OH), 
3092 (Fc CH). HRMS (ESI-TOF) m/z: [M]+ Calcd for C12H13FeIO 355.9360; 
Found 355.9361. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-hydroxyethyl-1-
iodo-ferrocene (6-(Sp)) (1.37 g, 3.85 mmol, 89 %) was prepared according 
to the same procedure from (Sp)-1-iodo-2-vinyl-ferrocene (5-(Sp)) (1.55 g, 
4.34 mmol). 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (7-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (6-(Rp)) (1.11 g, 3.13 mmol, 1.0 
eq.) was dissolved in dry DMF (25 ml) and stirred in a Schlenk tube under 
an atmosphere of argon. NaH (0.188 g, 7.83 mmol, 2.5 eq.) was added in 
small portions, the solution turned from orange to yellow and stirring was 
continued for 1 hr. BnBr (0.74 ml, 6.26 mmol, 2.0 eq.) was added and 
stirring continued for 16 hrs. The reaction was quenched by the dropwise 
addition of water, extracted with Et2O and dried over MgSO4. The solvent 
was removed in vacuo and the crude product was purified by flash column 
chromatography on silica gel using an eluent of hexane. The solvent was 
removed in vacuo to give the title compound as a yellow oil (1.40 g, 3.13 
mmol, 100 %). 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.12 (m, 5H (Ph CH)), 
4.43 (s, 2H (Ph C–CH2)), 4.28 (dd, J = 2.6, 1.3 Hz, 1H (Fc CH)), 4.11 (dd, 
J = 2.6, 1.3 Hz, 1H (Fc CH)), 4.03 (dd, J = 2.6, 2.6 Hz, 1H (Fc CH)), 3.99 
(s, 5H (cp CH)), 3.62 – 3.36 (m, 2H (CH2CH2O), 2.73 – 2.53 (m, 2H 
(CH2CH2O)). 13C NMR (400 MHz, CDCl3) δ 138.41 (Ph C–CH2), 128.39 
(Ph CH), 127.65 (Ph CH), 127.57 (Ph CH), 86.59 (Fc C–CH2), 74.03 (Fc 
CH), 72.93 (Ph C–CH2), 71.57 (cp CH), 70.24 (CH2CH2O), 68.28 (Fc CH), 
67.63 (Fc CH), 45.76 (Fc C–I), 30.63 (CH2CH2O). Ȟmax/cm-1 = 3088 (Fc 
CH), 3029 (Ph CH). HRMS (ESI-TOF) m/z: [M]+ Calcd for C19H19FeIO 
455.9830; Found 455.9827. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
iodo-ferrocene (7-(Sp)) (1.47 g, 3.30 mmol, 86 %) was prepared according 
to the same procedure from (Sp)-2-β-benzyloxyethyl-1-iodo-ferrocene (6-
(Sp)) (1.37 g, 3.85 mmol). 
(Rp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (7-(Rp)) (1.47 g, 3.28 mmol, 1.0 
eq.) was dissolved in dry Et2O (20 ml) with stirring and cooled to -78 °C in 
a Schlenk tube under argon. n-BuLi (2.5 M in hexane) (2.30 ml, 5.74 mmol, 
1.75 eq.) was added slowly and stirring continued at -78 °C for 0.5 hrs 
before the reaction mixture was warmed to room temperature over 0.5 hrs. 
After cooling again to -78 °C, DMF (0.76 ml, 9.84 mmol, 3.0 eq.) was added 
slowly and stirring continued for 0.5 hrs, the mixture was then allowed to 
warm to room temperature and stirring continued for 0.5 hrs. The reaction 
was quenched by the slow addition of water (10 ml), extracted with Et2O 
and dried over MgSO4. The solvent was removed in vacuo and the crude 
product purified by flash column chromatography on silica gel using a 
gradient eluent system of 0 → 30 % EtOAc in hexane. The solvent was 
removed in vacuo to give the title compound as a red oil (0.720 g, 2.07 
mmol, 63 %). 1H NMR (300 MHz, CDCl3) δ 10.01 (s, 1H (CHO)), 7.33 – 
7.18 (m, 6H (Ph CH)), 4.67 (dd, J = 2.7, 1.5 Hz, 1H (Fc CH)), 4.53 (dd, J = 
2.6, 1.5 Hz, 1H (Fc CH)), 4.45 (s, 2H, (Ph C–CH2)), 4.44 (dd, J = 2.7, 2.6 
Hz, 1H (Fc CH)), 4.14 (s, 5H (cp CH)), 3.63 – 3.47 (m, 2H (CH2CH2O)), 
3.04 (ddd, J = 14.5, 6.5, 6.5 Hz, 1H (Fc C–CH2)), 2.80 (ddd, J = 14.5, 6.8, 
6.8 Hz, 1H (Fc C–CH2)). 13C NMR (400 MHz, CDCl3) δ 193.82 (CHO), 
138.39 (Ph C–CH2), 128.41 (Ph CH), 127.65 (Ph CH), 127.60 (Ph CH), 
88.37 (Fc C–CH2), 77.13 (Fc C–CHO), 74.72 (Fc CH), 72.96 (Ph C–CH2), 
71.50 (Fc CH), 70.79 (CH2CH2O), 70.21 (cp CH), 70.17 (Fc CH), 28.86 
(CH2CH2O). Ȟmax/cm-1 = 3087 (Fc CH), 3029 (Ph CH), (CH), 2723 (OC–H), 
1669 (C=O). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C20H20FeO2Na 
371.0710; Found 371.0707. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
formyl-ferrocene (8-(Sp)) (1.05 g, 3.02 mmol, 91 %) was prepared 
according to the same procedure from (Sp)-2-β-benzyloxyethyl-1-iodo-
ferrocene (7-(Sp)) (1.47 g, 3.30 mmol). 
(Rp)-2-β-benzyloxyethyl-1-vinyl-ferrocene (9-(Rp)) 
Methyltriphenylphosphonium bromide (2.74 g, 7.67 mmol, 3.0 eq.), KOtBu 
(0.86 g, 7.67 mmol, 3.0 eq.) and dibenzo-18-crown-6 (0.005 g, 0.013 mmol, 
0.005 eq.) were dissolved in dry THF (20 ml) in a Schlenk tube under an 
atmosphere of argon and stirred for 30 mins at room temperature to 
produce a bright yellow solution. (Rp)-2-β-benzyloxyethyl-1-formyl-
ferrocene (8-(Rp)) (0.890 g, 2.56 mmol, 1.0 eq.) was dissolved in dry THF 
(20 ml) and added slowly, the resulting orange solution was stirred at room 
temperature for 1 hr. The reaction was quenched by the careful addition of 
water (20 ml), extracted with Et2O, dried over MgSO4 and the solvent 
removed in vacuo. The crude product was purified by flash column 
chromatography on neutralised (Et3N) silica gel using an eluent of 10 % 
EtOAc in hexane. The solvent was removed in vacuo to give the title 
compound as an orange oil (0.869 g, 2.51 mmol, 98 %). 1H NMR (300 MHz, 
CDCl3) δ 7.51 – 7.22 (m, 5H (Ph CH)), 6.58 (dd, J = 17.4, 10.9 Hz, 1H 
(CH=CH2)), 5.37 (dd, J = 17.4, 1.6 Hz, 1H (CH2=CH)), 5.09 (dd, J = 10.9, 
1.6 Hz, 1H (CH2=CH)), 4.53 (s, 2H (Ph C–CH2), 4.43 (dd, J = 2.6, 1.4 Hz, 
1H (Fc CH)), 4.20 (dd, J = 2.6, 1.4 Hz, 1H (Fc CH)), 4.15 (dd, J = 2.6 Hz, 
1H (Fc CH)), 4.03 (s, J = 2.7 Hz, 5H (cp CH)), 3.58 (m, 2H (CH2CH2O)), 
2.81 (m, 2H (CH2CH2O)). 13C NMR (400 MHz, CDCl3) δ 138.51 (Ph C–C), 
133.17 (CH=CH2), 128.48 (Ph CH), 127.76 (Ph CH), 127.66 (Ph CH), 
111.78 (CH2=CH), 84.12 (Fc C–CH2), 82.42 (Fc C–CH), 73.10 (Ph C–CH2), 
71.05 (CH2CH2O), 69.88 (cp CH), 69.78 (Fc CH), 67.20 (Fc CH), 64.78 (Fc 
CH), 28.84 (CH2CH2O). Ȟmax/cm-1 = 3085 (Fc CH), 3029 (Ph CH), 1626 
(C=C). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C21H22FeONa 369.0918; 
Found 369.0905. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
vinyl-ferrocene (9-(Sp)) (0.476 g, 1.37 mmol, 91 %) was prepared 
according to the same procedure from (Sp)-2-β-benzyloxyethyl-1-formyl-
ferrocene (8-(Sp)) (0.526 g, 1.51 mmol). 
(Sp)-1-β-benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-(Sp)) 
(Rp)-2-β-benzyloxyethyl-1-vinyl-ferrocene (9-(Rp)) (0.869 g, 2.51 mmol, 
1.0 eq) was dissolved in dry THF (15 ml) in a Schlenk tube under an 
atmosphere of argon and cooled to 0 °C in an ice bath. BH3•THF (1M in 
THF) (3.76 ml, 3.76 mmol, 1.5 eq.) was added dropwise and stirring 
continued at 0 °C for 15 mins before the solution was warmed to room 
temperature and stirring continued for another 1.5 hrs. The solution was 
cooled to 0 °C before EtOH (6.0 ml) was carefully added and stirring 
continued for 5 min, followed by the dropwise addition of NaOH (3M in 
H2O) (6.0 ml) and a further 10 min of stirring. H2O2 (30 % in H2O) (6.0 ml) 
was then added slowly and stirring continued for 30 min and the solution 
allowed to warm to room temperature. The reaction was extracted with 
Et2O, washed with water (2 x 50 ml) and dried over MgSO4. The solvent 
was removed in vacuo and the crude product purified by flash column 
chromatography through a short column of neutralised (Et3N) silica gel 
using an eluent of 10 % EtOAc in hexane. The solvent was removed in 
vacuo to give the title compound as an orange oil (0.802 g, 2.20 mmol, 
88 %). 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.24 (m, 5H (Ph CH)), 4.49 (s, 
2H (Ph C–CH2)), 4.14 – 4.07 (m, 2H (Fc CH)), 4.06 – 4.03 (m, 1H (Fc CH)), 
4.02 (s, 5H (cp CH)) 3.76 – 3.45 (m, 4H (CH2CH2OCH2, CH2OH)), 2.79 – 
    
 
 
 
 
 
2.54 (m, 4H (CH2CH2OCH2, CH2CH2OH)), 2.18 (t, J = 5.9 Hz, 1H (OH)). 
13C NMR (400 MHz, CDCl3) δ 138.23 (Ph C–CH2), 128.51 (Ph CH), 127.86 
(Ph CH), 127.77 (Ph CH), 84.71 (Fc C–CH2CH2OCH2), 84.35 (Fc C–
CH2CH2OH), 73.13 (Ph C–CH2), 71.03 (CH2CH2OCH2), 69.35 (cp CH), 
68.31 (Fc CH), 68.21 (Fc CH), 66.32 (Fc CH), 63.67 (CH2CH2OH), 31.68 
(CH2CH2OH), 28.68 (CH2CH2OCH2). Ȟmax/cm-1 = 3381 (OH), 3089 (Fc CH), 
3030 (Ph CH). HRMS (ESI-TOF) m/z: [M]+ Calcd for C21H24FeO 364.1126; 
Found 364.1120. 
Producing matching 1H and 13C NMR spectra, (Rp)-1-β-benzyloxyethyl-2-
β-hydroxyethyl-ferrocene (10-(Rp)) (0.413 g, 1.13 mmol, 82 %) was 
prepared according to the same procedure from (Sp)-2-β-benzyloxyethyl-
1-vinyl-ferrocene (9-(Sp)) (0.476 g, 1.37 mmol). 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene 
(11-(Sp)) 
Triphenylphosphine (0.262 g, 1.00 mmol, 2.0 eq.) and N3-benzoylthymine 
(0.173 g, 0.75 mmol, 1.5 eq.) were dissolved in dry THF (5 ml) and stirred 
under an atmosphere of argon in a schlenk tube wrapped in foil. (Sp)-1-β-
benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-(Sp)) (0.182 g, 0.50 mmol, 
1.0 eq.) dissolved in dry THF (5 ml) was added, followed by diethyl 
azodicarboxylate (0.20 ml, 1.00 mmol, 2.0 eq.) and the reaction mixture 
stirred at 75 °C for 1 hr. The reaction was quenched with brine (5 ml), 
extracted with Et2O and dried over MgSO4. The solvent was removed in 
vacuo and the crude product purified by flash column chromatography on 
neutralised (Et3N) silica gel using a gradient eluent system of 30 → 50 % 
EtOAc in hexane. The solvent was removed in vacuo to give the title 
compound as an orange solid (0.213 g, 0.370 mmol, 74 %). m.p. 57 °C. 1H 
NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 8.3, 1.3 Hz, 2H (Bz CH)), 7.63 (tt, 
J = 7.5, 1.3 Hz, 1H ((Bz CH)), 7.48 (dd, J = 8.3, 7.5 Hz, 2H (Bz CH)), 7.36 
– 7.25 (m, 5H (Bn CH)), 6.67 (d, J = 1.2 Hz, 1H (CH=C)), 4.49 (s, 1H (Bn 
CH2O)), 4.48 (s, 1H (Bn CH2O)), 4.15 (dd, J = 2.5, 1.3 Hz, 1H (Fc CH)), 
4.04 (dd, J = 2.5, 2.5 Hz, 1H (Fc CH)), 4.03 (s, 5H (cp CH)), 3.96 (dd, J = 
2.5, 1.3 Hz, 1H (Fc CH)), 3.76 (dd, J = 8.0, 6.6 Hz, 2H (CH2N)), 3.70 (ddd, 
J = 8.9, 5.6, 5.5 Hz, 1H (CH2CH2O)), 3.57 (ddd, J = 8.9, 7.1, 7.1 Hz, 1H 
(CH2CH2O)), 2.88 – 2.58 (m, 4H (CH2CH2O, CH2CH2N)), 1.78 (d, J = 1.2 
Hz, 3H (CH3)). 13C NMR (400 MHz, CDCl3) δ 169.30 (Bz CO), 163.31 
(C=C–CO–N), 149.70 (N–CO–N), 140.95 (CH=C), 138.08 (Bn C–CH2), 
134.97 (Bz CH), 131.72 (Bz C–CO), 130.45 (Bz CH), 129.16 (Bz CH), 
128.47 (Bn CH), 127.95 (Bn CH), 127.82 (Bn CH), 109.62 (C=CH), 84.75 
(Fc C–CH2CH2O), 82.58 (Fc C–CH2CH2N), 73.25 (Bn C–CH2), 71.40 
(CH2CH2O), 69.32 (cp CH), 68.45 (Fc CH), 68.38 (Fc CH), 66.41 (Fc CH), 
49.54 (CH2N), 28.62 (CH2CH2O), 27.67 (CH2CH2N), 12.26 (CH3). Ȟmax/cm-
1
 = 3075 (Fc CH), 1744 (C=O), 1696 (C=O), 1646 (C=O), 1599 (C=C). 
HRMS (ESI-TOF) m/z: [M]+ Calcd for C33H32FeN2O4 576.1711; Found 
576.1715. 
Producing matching 1H and 13C NMR spectra, (Rp)-2-β-(N3-
benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-(Rp)) (0.241 g, 
0.417 mmol, 37 %) was prepared according to the same procedure from 
(Rp)-1-β-benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-(Rp)) (0.413 g, 
1.13 mmol). 
(Sp)-1-β-hydroxyethyl-2-β-thyminylethyl-ferrocene (2-(Sp)) 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-
(Rp)) (0.213 g, 0.370 mmol) was dissolved in EtOAc (5 ml) and hydrogen 
gas bubbled through the solution with stirring using a balloon and needle. 
Pd(OH)2/C (0.30 g) was added and the resulting mixture stirred at room 
temperature with bubbling and stirring for 1 hr. The mixture was filtered 
through a short pad of celite, washed with water (2 x 5 ml) and dried over 
MgSO4. The crude product was dissolved in minimal hot EtOAc and 
allowed to cool, the title compound precipitated out as orange crystals 
which were collected by filtration and dried in vacuo (0.108 g, 0.283 mmol, 
76 %). m.p. 197 °C. [�]D25 = -4 (±3) (c = 0.375 in methanol). 1H NMR (400 
MHz, CDCl3) δ 10.02 (s, 1H, NH), 6.93 (d, J = 1.1 Hz, 1H (CH=C)), 4.13 
(dd, J = 2.4, 1.3 Hz, 1H (Fc CH)), 4.04 (s, 5H, (cp CH)), 4.03 (dd, J = 2.4, 
2.4 Hz, 1H (Fc CH), 3.95 (dd, J = 2.4, 1.3 Hz, 1H (Fc CH)), 3.85 – 3.60 (m, 
4H (CH2N, CH2OH)), 3.20 (t, J = 5.3 Hz, 1H (OH)), 2.81 (ddd, J = 13.6, 9.1, 
4.3 Hz, 1H (CH2CH2N)), 2.71 – 261 (m, 3H, (CH2CH2OH, CH2CH2N)), 1.90 
(d, J = 1.1 Hz, 3H (CH3)). 13C NM R (101 MHz, CDCl3) δ 164.60 (C=C–
CO–N), 151.57 (N–CO–N), 140.63 (CH=C), 111.02 (C=CH), 84.35 (Fc C–
CH2CH2OH), 82.47 (Fc C–CH2CH2N), 69.41 (cp CH), 68.85 (Fc CH), 68.33 
(Fc CH), 66.65 (Fc CH), 63.69 (CH2OH), 50.09 (CH2N), 31.67 
(CH2CH2OH), 28.20 (CH2CH2N), 12.44 (CH3). Ȟmax/cm-1 = 3477 (OH), 3149 
(NH), 3019 (NH), 1735.51 (C=O), 1664.05 (C=C). HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C19H22FeN2O3Na 405.0878; Found 405.0874. Anal. 
Calcd for C19H22FeN2O3: C, 59.70; H, 5.80; N, 7.33. Anal. Found C, 59.67; 
H, 5.75; N, 7.52. 
(Rp)-1-β-hydroxyethyl-2-β-thyminylethyl-ferrocene (2-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-
(Rp)) (0.240 g, 0.417 mmol) was dissolved in EtOAc (5 ml) and hydrogen 
gas bubbled through the solution using a balloon and needle with stirring. 
Pd(OH)2/C (0.30 g) was added and the resulting mixture stirred at room 
temperature with gentle bubbling and stirring for 30 mins. The mixture was 
filtered through a short pad of celite, washed with water (2 x 5 ml) and dried 
over MgSO4. The solvent was removed in vacuo and the alcohol purified 
by flash column chromatography on silica gel using an eluent of EtOAc. 1H 
and 13C NMR confirmed the successful removal of the benzyl group. The 
residue was then dissolved in NH3 (7N in MeOH) and stirred at room 
temperature for 1 hr before the solvent was removed in vacuo. The crude 
product was purified by flash column chromatography on silica gel using 
an eluent of EtOAc. Recrystalisation from hot EtOAc produced orange 
crystals which were collected by filtration and dried in vacuo to give the 
title compound (0.111 g, 0.290 mmol, 70 %). [�]D25 = +3 (±3) (c = 0.345 in 
methanol).  1H and 13C NMR spectra match (Sp)-1-β-hydroxyethyl-2-β-
thyminylethyl-ferrocene (2-(Sp)). Anal. Calcd for C19H22FeN2O3: C, 59.70; 
H, 5.80; N, 7.33. Found: C, 59.81; H, 5.99; N, 7.14. 
(Rp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)-ferrocene (12-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Rp)) (0.720 g, 2.07 mmol, 
1.0 eq.) was dissolved in dry DCM (20 ml) in a Schlenk tube under an 
atmosphere of argon and 4 Å molecular sieves (ca. 0.1 g) were added with 
stirring. 3,3-dimethylpentane-1,5-diol (0.431 g, 4.14 mmol, 2.0 eq.) was 
added, followed by PTSA (0.040 g, 0.21 mmol, 0.10 eq.) and the reaction 
mixture stirred under argon for 4 hrs. The reaction was quenched by the 
addition of anhydrous K2CO3 (0.25 g) and stirring continued for 10 minutes. 
The mixture was filtered through a small pad of celite, dried over MgSO4 
and the solvent removed in vacuo. The crude product was purified by flash 
column chromatography on neutralised (Et3N) silica gel using an eluent of 
10 % EtOAc in hexane. The solvent was removed in vacuo to give the title 
compound as an orange oil (0.772 g, 1.78 mmol, 86 %). 1H NMR (400 MHz, 
CDCl3) δ 7.42 – 7.23 (m, 5H Ph CH)), 5.27 (s, 1H (CHOO)), 4.51 (2 x s, 
2H (Ph C–CH2)), 4.31 (dd, J = 2.5, 1.5 Hz, 1H (Fc CH)), 4.09 (s, 6H (cp 
CH, Fc CH)), 4.03 (dd, J = 2.5 Hz, 2.4 Hz 1H (Fc CH)), 3.77 – 3.44 (m, 6H 
(CH2CH2O, OCH2C(CH3)2)), 2.85 (ddd, J = 14.0, 9.1, 5.7 Hz, 1H (Fc C–
CH2)), 2.71 (ddd, J = 14.0, 9.4, 6.2 Hz, 1H (Fc C–CH2)), 1.23 (s, 3H (CH3)), 
0.76 (s, 3H (CH3)). 13C NMR (101 MHz, CDCl3) δ 138.71 (Ph C–CH2), 
128.47 (Ph CH), 127.86 (Ph CH), 127.63 (Ph CH), 100.68 (CHOO), 84.29 
(Fc C–CHOO), 83.30 (Fc C–CH2), 77.88 (OCH2C(CH3)2), 77.78 
(OCH2C(CH3)2), 73.06 (Ph C–CH2), 71.17 (CH2CH2O), 69.53 (Fc CH), 
69.50 (cp CH), 66.76 (Fc CH), 66.52 (Fc CH), 30.22 (C(CH3)2), 28.88 
(CH2CH2O), 23.24 (CH3), 22.05 (CH3). Ȟmax/cm-1 = 3090 (Fc CH), 3031 (Ph 
CH). HRMS (ESI-TOF) m/z: [M]+ Calcd for C25H30FeO3 434.1544; Found 
434.1545. 
    
 
 
 
 
 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-ferrocene (12-(Sp)) (0.586 g, 
1.35 mmol, 89 %) was prepared according to the same procedure from 
(Sp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Sp)) (0.526 g, 1.51 g). 
(Rp)-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-2-β-hydroxyethyl-
ferrocene (13-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-
ferrocene (12-(Rp)) (0.538 g, 1.24 mmol) was dissolved in dry DMF (10 ml) 
in a round bottomed flask fitted with a rubber septum. A balloon of 
hydrogen was fitted with a long needle and the gas bubbled through the 
solution; a second needle through the septum allowed the pressure to 
equalise. Pd(OH)2/C (0.30 g) was added and the solution carefully stirred 
with continued bubbling of hydrogen gas. The reaction was carefully 
monitored by TLC until, after 20 minutes all starting material was 
consumed. The hydrogen balloon was removed and the reaction mixture 
filtered through a small pad of celite. Brine (20 ml) was added, the crude 
product extracted with Et2O and dried over MgSO4. The crude product was 
then purified by flash column chromatography on neutralised (Et3N) silica 
gel using an eluent of 30 % EtOAc in hexane. The solvent was removed in 
vacuo to give the title compound as an orange oil (0.305 g, 0.885 mmol, 
71 %). 1H NMR (400 MHz, CDCl3) δ 5.31 (s, 1H (CH)), 4.37 (dd, J = 2.0, 
2.0 Hz, 1H (Fc CH)), 4.11 (s, 5H (cp CH)), 4.10 – 4.07 (m, 2H (Fc CH)), 
3.80 – 3.69 (m, 1H (CH2OH)), 3.75 (dd, J = 11.1, 2.5 Hz, 1H (CH2OCH)), 
3.67 (dd, J = 11.0, 2.6 Hz, 1H (CH2OCH)), 3.61 (dd, J = 11.1, 0.9 Hz, 1H 
(CH2OCH)), 3.60 (dd, J = 11.0, 0.9 Hz, 1H (CH2OCH)) 3.59 – 3.51 (m, 1H 
(CH2OH)), 2.76 (ddd, J = 14.5, 8.7, 4.7 Hz, 1H (CH2CH2OH)), 2.75 (s, 1H 
(OH)) 2.63 (ddd, J = 14.5, 5.5, 4.2 Hz, 1H (CH2CH2OH)), 1.23 (s, 3H (CH3), 
0.77 (s, 3H (CH3)). 13C NMR (101 MHz, CDCl3) δ 100.55 (CH), 84.43 (Fc 
C–CH), 84.06 (Fc C–CH2), 77.90 (CH2OCH), 77.71 (CH2OCH), 69.72 (Fc 
CH), 69.57 (cp CH), 67.08 (Fc CH), 66.91 (Fc CH), 64.14 (CH2OH), 32.11 
(CH2CH2OH), 30.20 (C(CH3)2), 23.18 (CH3), 21.97 (CH3). Ȟmax/cm-1 = 3420 
(OH), 3095 (Fc CH). HRMS (ESI-TOF) m/z: [M]+ Calcd for C18H24FeO3 
344.1075; Found 344.1084. 
Producing matching 1H and 13C NMR spectra, (Sp)-1-formyl-(3,3-dimethyl-
1,5-pentanediol-acetal)-2-β-hydroxyethyl-ferrocene (13-(Sp)) (0.367 g, 
1.066 mmol, 79 %) was prepared according to the same procedure from 
(Sp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-
ferrocene (12-(Sp)) (0.583 g, 1.34 mmol). 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)ferrocene (14-(Rp)) 
Triphenylphosphine (0.596 g, 2.27 mmol, 1.5 eq.) and N3-benzoylthymine 
(0.454 g, 1.97 mmol, 1.3 eq.) were dissolved in dry THF (10 ml) and stirred 
under an atmosphere of argon in a schlenk tube wrapped in foil. (Rp)-1-
formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-2-β-hydroxyethyl-ferrocene 
(13-(Rp)) (0.522 g, 1.52 mmol, 1.0 eq.) dissolved in dry THF (10 ml) was 
added, followed by diethyl azodicarboxylate (0.45 ml, 2.27 mmol, 1.5 eq.) 
and the reaction mixture stirred at 75 °C for 2 hrs. The reaction was 
quenched with brine (10 ml), extracted with Et2O and dried over MgSO4. 
The solvent was removed in vacuo and the crude product purified by flash 
column chromatography on neutralised (Et3N) silica gel using a gradient 
eluent system of 10 → 40 % EtOAc in hexane. The solvent was removed 
in vacuo to give the title compound as an yellow solid (0.221 g, 0.398 mmol, 
65 %). m.p. 87 °C. 1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 8.1, 1.2 Hz, 
2H (Ph CH)), 7.63 (tt, J = 7.4, 1.2 Hz, 1H (Ph CH)), 7.48 (dd, J = 8.1, 7.4 
Hz, 2H (Ph CH)), 6.78 (d, J = 1.0 Hz, 1H (CH=C)), 5.30 (s, 1H (CHOO)), 
4.34 (dd, J = 2.4, 1.5 Hz, 1H (Fc CH)), 4.11 (s, 5H (cp CH)), 4.06 (dd, J = 
2.4, 2.2 Hz, 1H (Fc CH)), 4.05 – 3.96 (m, 1H (CH2N)), 3.95 (dd, J = 2.2, 
1.5 Hz, 1H (Fc CH)), 3.76 – 3.67 (m, 3H (CH2N, CH2O)), 3.61 (d, J = 10.7 
Hz, 2H (CH2O), 2.94 (ddd, J = 14.0, 6.8, 4.4 Hz, 1H (OCH2C(CH3)2)), 2.77 
(ddd, J = 14.0, 8.4, 7.6 Hz, 1H (OCH2C(CH3)2)), 1.79 (d, J = 1.0 Hz, 3H 
(CH3C=CH)), 1.24 (s, 3H (CH3CCH3)), 0.78 (s, 3H (CH3CCH3)). 13C NMR 
(101 MHz, CDCl3) δ 169.36 (Bz CO), 163.46 (C–CO–N), 149.77 (N–CO–
N), 141.51 (CH=C), 134.94 (Ph CH), 131.83 (Ph C–CO), 130.49 (Ph CH), 
129.16 (Ph CH), 109.42 (C=CH), 100.95 (CHOO), 84.06 (Fc C–CH), 81.97 
(Fc C–CH2), 77.91 (CH2O), 77.79 (CH2O), 70.01 (Fc CH), 69.63 (cp CH), 
67.83 (Fc CH), 66.87 (Fc CH), 50.06 (CH2N), 30.16 (C(CH3)2), 27.92 
(CH2CH2N), 23.32 (CH3CCH3), 21.97 (CH3CCH3), 12.21 (CH3C=CH). 
Ȟmax/cm-1 = 3088 (Fc CH), 1745 (C=O), 1697 (C=O), 1647 (C=O), 1599 
(C=C). HRMS (ESI-TOF) m/z: [M]+ Calcd for C30H32FeN2O5 556.1661; 
Found 556.1669. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)ferrocene (14-(Sp)) (0.456 g, 0.819 mmol, 77 %) was prepared 
according to the same procedure from (Sp)-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)-2-β-hydroxyethyl-ferrocene (13-(Sp)) (0.367 g, 1.07 
mmol). 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)ferrocene (14-(Rp)) (0.329 g, 0.591 mmol, 1.0 eq.) was 
dissolved in a mixture of THF (8 ml) and water (2ml) to produce a yellow 
solution. PTSA (0.056 g, 0.296 mmol, 0.5 eq.) was added and the resulting 
mixture stirred at room temperature for 45 min to produce a red solution. 
The reaction was quenched by the slow addition of sat. NaHCO3 solution, 
extracted with EtO2, dried over MgSO4 and the solvent removed in vacuo. 
The crude product was purified by flash column chromatography using an 
eluent of 50 % EtOAc in hexane and the solvent was removed in vacuo to 
give the title compound as an red solid (0.277 g, 0.589 mmol, 100 %). m.p. 
69 °C. 1H NMR (300 MHz, CDCl3) δ 10.01 (s, 1H (CHO)), 7.94 (dd, J = 8.4, 
1.3 Hz, 2H (Ph CH)), 7.64 (tt, J = 7.4, 1.3 Hz, 1H (Ph CH)), 7.50 (dd, J = 
8.4, 1.3 Hz, 2H (Ph CH)), 7.02 (d, J = 1.2 Hz, 1H (CH=C)), 4.70 (dd, J = 
2.7, 1.4 Hz, 1H (Fc CH)), 4.53 (dd, J = 2.6, 1.5 Hz, 1H (Fc CH)), 4.50 (dd, 
J = 2.6 Hz, 1H (Fc CH)), 4.24 (s, J = 4.0 Hz, 5H (cp CH)), 3.98 (ddd, J = 
13.4, 8.4, 7.0 Hz, 1H (CH2N)), 3.69 (ddd, J = 13.6, 8.7, 5.1 Hz, 1H (CH2N)), 
3.21 (ddd, J = 13.5, 8.4, 5.1 Hz, 1H (CH2)), 2.93 (ddd, J = 13.6, 8.5, 7.1 
Hz, 1H (CH2)), 1.89 (d, J = 1.0 Hz, 3H (CH3)). 13C NMR (101 MHz, CDCl3) 
δ 194.49 (CHO), 169.34 (Bz CO), 163.41 (C–CO–N), 149.89 (N–CO–N), 
140.82 (CH=C), 135.04 (Ph CH), 131.84 (Ph C–CO), 130.62 (Ph CH), 
129.22 (Ph CH), 110.36 (C=CH), 85.16 (Fc C–CH2), 75.47 (Fc CH), 73.03 
(Fc CH), 72.03 (Fc CH), 70.49 (cp CH), 50.01 (CH2N), 29.80 (Fc C–CO), 
28.58 (CH2CH2N), 12.37 (CH3). Ȟmax/cm-1 = 3068 (Ph CH), 1741 (C=O), 
1694 (C=O), 1641 (C=O), 1598 (C=C). HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C25H22FeN2O4Na 493.0827; Found 493.0825. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Sp)) (0.333 g, 0.707 mmol, 
86 %) was prepared according to the same procedure from (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)ferrocene (14-(Sp)) (0.454 g, 0.819 mmol). 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-
(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Rp)) (0.055 g, 
0.117 mmol, 1.0 eq.) was dissolved in MeOH (5 ml) and cooled to 0 °C 
with stirring. NaBH4 (0.008 g, 0.233 mmol, 2.0 eq.) was added to the red 
solution and stirring continued for 15 min at 0 °C. The resulting yellow 
solution was quenched with brine, extracted with DCM and dried over 
MgSO4. The crude product was purified by flash column chromatography 
using an eluent of 40 % hexane in EtOAc, the solvent was removed in 
vacuo to give the title compound as a yellow oil (0.053 g, 0.113 mmol, 
96 %). 1H NMR (400 MHz, CDCl3) δ 7.87 (dd, J = 8.2, 1.3 Hz, 2H (Ph CH)), 
7.71 – 7.58 (m, J = 7.5, 1.3 Hz, 1H (Ph CH)), 7.48 (dd, J = 8.2, 7.5 Hz, 2H 
(Ph CH)), 6.93 (d, J = 1.2 Hz, 1H (CH=C)), 4.47 (d, J = 11.9 Hz, 1H 
(CH2OH)), 4.31 (d, J = 11.9 Hz, 1H (CH2OH)), 4.19 (s, 1H (Fc CH)), 4.11 
    
 
 
 
 
 
(t, J = 2.1 Hz, 1H (Fc CH)), 4.08 (s, 5H (cp CH)), 4.04 (s, 1H (Fc CH)), 3.91 
(ddd, J = 13.7, 8.5, 7.4 Hz, 1H (CH2CH2N)), 3.76 (ddd, J = 13.6, 7.8, 4.4 
Hz, 1H (CH2CH2N)), 2.85 (ddd, J = 14.2, 7.3, 4.4 Hz, 1H (CH2CH2N)), 2.74 
(dt, J = 14.2, 8.2 Hz, 1H (CH2CH2N)), 2.40 (s, 1H (OH)), 1.86 (d, J = 1.2 
Hz, 3H (CH3)). 13C NMR (101 MHz, CDCl3) δ 169.27 (Bz CO), 163.34 (C–
CO–N), 150.06 (N–CO–N), 140.69 (CH=C), 135.09 (Ph CH), 131.67(Ph 
C–CO), 130.62 (Ph CH), 129.20 (Ph CH), 110.43 (C=CH), 85.57 (Fc C–
CH2CH2), 83.04 (Fc C–CH2OH), 70.04 (Fc CH), 69.93 (Fc CH), 69.22 (cp 
CH), 67.19 (Fc CH), 59.45 (CH2OH), 49.90 (CH2N), 27.85 (CH2CH2N), 
12.33 (CH3). Ȟmax/cm-1 = 3474 (OH), 3072 (Ph CH), 1743 (C=O), 1693 
(C=O), 1639 (C=O), 1599 (C=C). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C25H24FeN2O4Na 495.0983; Found 495.0972. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Sp)) (0.329 g, 
0.697 mmol, 99 %) was prepared according to the same procedure from 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Sp)) (0.333 g, 
0.707 mmol). 
(Rp)-1-hydroxymethyl-2-β-thyminylethyl-ferrocene (3-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Rp)) 
(0.0327 g, 0.069 mmol) was dissolved in MeOH (2 ml) before excess 
MeNH2 (30 % in MeOH) (0.2 ml) was added and the resulting mixture was 
stirred at room temperature for 5 min. Brine (5 ml) was added, the crude 
product extracted with DCM, dried over MgSO4 and the solvent removed 
in vacuo. The crude product was purified by flash column chromatography 
on silica gel using an eluent of 20 % hexane in EtOAc. Recrystallisation by 
the slow evaporation of a concentrated solution in chloroform produced 
orange crystals and the solvent was removed in vacuo to give an orange 
solid. Recrystallisation from a concentrated solution in chloroform 
produced single orange crystals of the title compound (0.025 g, 0.067 
mmol, 93 %). Decomposes above 159 °C. [�]D25 = -9 (±3) (c = 0.25 in 
methanol). 1H NMR (300 MHz, CDCl3) δ 8.68 (s, 1H (NH)), 6.82 (d, J = 1.2 
Hz, 1H (CH=C)), 4.52 (d, J = 12.0 Hz, 1H (CH2OH)), 4.37 (d, J = 12.0 Hz, 
1H (CH2OH)), 4.20 (dd, J = 2.5, 1.4 Hz, 1H (Fc CH)), 4.17 – 4.10 (m, 1H 
(Fc CH)), 4.08 (s, 5H (cp CH)) 4.00 (dd, J = 2.3, 1.4 Hz, 1H (Fc CH)), 3.81 
(dd, J = 8.3, 1.3 Hz, 1H (CH2N)), 3.79 (d, J = 8.3 Hz, 1H (CH2N)), 2.89 – 
2.66 (m, 2H (CH2CH2N)), 2.17 (s, 1H (OH)), 1.85 (d, J = 1.2 Hz, 3H (CH3)). 
13C NMR (101 MHz, CDCl3) δ 164.12 (C–CO–N), 150.99 (N–CO–N), 
140.89 (CH=C), 110.47 (C=CH), 85.65 (Fc C–CH2CH2), 83.11 (Fc C–
CH2OH), 70.01 (Fc CH), 69.73 (Fc CH), 69.11 (cp CH), 67.14 (Fc CH), 
59.56 (CH2OH), 49.97 (CH2N), 28.05 (CH2CH2N), 12.32 (CH3). Ȟmax/cm-1 
= 3411 (OH), 1658 (C=O), 1627 (C=C). HRMS (ESI-TOF) m/z: [M]+ Calcd 
for C18H20FeN2O3 368.0823; Found 368.0811. Anal. Calcd for 
C18H20FeN2O3: C, 58.72; H, 5.48; N, 7.61. Found: C, 58.91; H, 5.45; N, 
7.74.  
Producing matching 1H and 13C NMR spectra, (Sp)-1-hydroxymethyl-2-β-
thyminylethyl-ferrocene (3-(Sp)) (0.245 g, 0.665 mmol, 95 %) was 
prepared according to the same procedure from (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Sp)) (0.329 g, 
0.697 mmol). [�]D25  = +3 (±3) (c = 0.28 in methanol). Anal. Calcd for 
C18H20FeN2O3: C, 58.72; H, 5.48; N, 7.61Anal. Found C, 58.80; H, 5.55; N, 
7.47. 
Electrochemistry 
Electrochemical measurements were performed in dry and de-oxygenated 
acetonitrile solutions. The base electrolyte was 0.1 M tetrabutylammonium 
hexafluorophosphate (TBAPF6, ≥ 99%, Fluka). Solutions of compounds 1-
(Rp), 2-(Rp), and 3-(Rp) were made in this electrolyte at concentrations of 
1.0 mM and 1 mM decamethylferrocene (dmfc) was added to serve as an 
internal reference. (The measured E1/2 of dmfc vs ferrocene in this 
electrolyte was the literature.[10] The 
measurements were performed on a BioAnalytical Systems Inc. (West 
Lafayette, IN) EC epsilon potentiostat using a C3 cell stand and a 
traditional 3-electrode set-up. Measurements were carried out at room 
temperature. All electrodes were purchased from IJ Cambria (Llanelli, 
Wales). The working electrode was a glassy carbon electrode of 3 mm 
diameter, the counter electrode was a platinum wire and the reference 
electrode was a Ag|AgCl|3 M KCl electrode (BASi), housed in a 
compartment connected to the cell via a frit. 
Prior to use, all glassware was cleaned by immersing in a 1:1 mixture of 
ammonia (35%) and hydrogen peroxide (30%) for several hours and then 
rinsed with copious quantities of ultrapure water (purified with a Millipore 
tandem Elix-A10 system, resistivity > 18 MΩ cm, TOC < 5 ppb). The 
glassware was soaked overnight in ultrapure water and dried carefully 
before use. The counter electrode was prepared by flame annealing and 
the reference electrode was rinsed with acetonitrile before each use. The 
working electrode was prepared by polishing in successively finer grades 
of alumina slurry (1.0 ȝm, 0.3 ȝm, 0.05 ȝm), rinsed with ultrapure water 
and then acetonitrile. It was carefully dried under a stream of argon and 
placed in the electrochemical cell containing the test solution. Molecular 
sieves were used to maintain dryness of the solvent and an argon blanket 
was maintained in the cell during the measurements. 
 
Biological Studies 
Cell culture: HOS osteosarcoma cells (87070202) were obtained from the 
European General Cell culture collection and routinely cultured in T75 cell 
culture flasks using DMEM supplemented with 10% v/v foetal calf serum, 
2 mM glutamine, 100U/ml penicillin and 100ȝg/ml streptomycin. Cells were 
passaged twice weekly using a trypsin-EDTA solution and reseeded in a 
fresh T75 flask at an approximate dilution of 1:3.  
Crystal violet assay: Cells were seeded in a 96-well plate at a density of 
6250 cells per well in 100 ȝL of media and left to attach overnight. The 
next day the media was removed and replaced with fresh media containing 
the appropriate concentration of test compound prepared from a 10 mM 
stock solution of test compound dissolved in DMSO (storage of 1-(S,Rp) in 
this solvent over a period of 12 months at 4 oC gave no evidence of 
degradation, as monitored by 1-H NMR).  All compounds were fully soluble 
in PBS buffer at the concentrations used; the final concentration of DMSO 
in all wells was 1% v/v. After 4 days incubation the media was removed 
and wells washed with 100ȝl of phosphate buffered saline solution (PBS). 
Next, 4% paraformaldehyde (100  ȝL  per well) was added and the plates 
incubated at room temperature for 15 minutes to allow fixation of the cells. 
The paraformaldehyde was removed and crystal violet (100 ȝl of 0.5% w/v, 
dissolved in 10% ethanol, 90% distilled water) added and plates left at 
room temperature for 20 minutes to allow staining of the cells. The crystal 
violet solution was removed and wells were washed three times with 100 
ȝl of distilled water and allowed to air dry for approximately 20 minutes. 
Once the cells were dry, 100 ȝl of 10% v/v acetic acid was added to each 
well and the plates were left at room temperature for 20 minutes to allow 
the stain to dissolve. Absorbance was read at 590 nm wavelength against 
a blank of acetic acid solution alone in a plate reader. 
X-Ray Crystallography  
Table 2. Selected crystal data for 2-(Rp), 2-(Sp), 3-(Rp) and 3-(Sp) 
 
2-(Rp) 2-(Sp) 3-(Rp) 3-(Sp) 
Empirical 
Formula 
C19H22FeN2
O3 
C19H22FeN
2O3 
C18H20FeN
2O3 
C18H20FeN
2O3 
    
 
 
 
 
 
Formula 
Weight 382.23 382.23 368.21 368.21 
Temperat
ure (K) 100.01(10) 100.0(3) 99.98(12) 100.00(10)  
Crystal 
System Tetragonal 
Orthorhom
bic 
Orthorhom
bic 
Orthorhom
bic 
Space 
Group 
P43212 (no. 
96) 
P212121 
(no. 19) 
P212121 
(no. 19) 
P212121 
(no. 19) 
a ; b ; c  
(Å) 
11.96948(1
0) ; 
11.96948(1
0) ; 
24.1571(3) 
11.8672(3) 
;  
12.1205(3) 
; 
24.1747(5) 
11.3617(3) 
; 
11.8847(3) 
;  
23.7138(6) 
11.3958(6) 
;  
11.8730(6) 
; 
23.7314(10
) 
V (Å3) 3460.95(7) 3477.19(13) 
3202.07(14
) 3210.9(3) 
Z ν Z’ 8 ; 1 8 ; 2 8 ; 2 8 ; 2 calc 
(g/cm3) 1.467 1.460 1.528 1.523 
ȝ(MoKα) 
(mm-1) 0.892 0.888 0.961 0.958  (Å) 0.71073 0.71073 0.71073 0.71073 
F(000) 1600.0 1600.0 1536.0 1536.0 
2 Range 
for Data 
Collection 
() 
4.792 – 
58.954 
4.76 – 
52.74 
6.856 – 
54.962 
4.954 – 
56.56 
Index 
Ranges 
-16 ≤ h ≤ 
15, 
-15 ≤ k ≤ 
16, 
-31 ≤ l ≤ 33 
-14 ≤ h ≤ 
14, 
-15 ≤ k ≤ 
15, 
-30 ≤ l ≤ 29 
-14 ≤ h ≤ 
14, 
-14 ≤ k ≤ 
15, 
-30 ≤ l ≤ 30 
-14 ≤ h ≤ 
10, 
-14 ≤ k ≤ 
15, 
-29 ≤ l ≤ 31 
Reflection
s 
Collected 
71538 35875 34740 24084 
Independ
ent 
Reflection
s 
4700 [Rint = 
0.0401] 
7092 [Rint = 
0.0418] 
7237 [Rint = 
0.0381] 
7488 [Rint = 
0.0481] 
Goodness
-of-Fit on 
F2 
1.085 1.053 1.097 1.132 
Final R 
Indices 
[I>=2σ (I)] 
R1 = 
0.0410,  
wR2 = 
0.0948 
R1 = 
0.0571,  
wR2 = 
0.1389 
R1 = 
0.0318,  
wR2 = 
0.0743 
R1 = 
0.0495,  
wR2 = 
0.1091 
Final R 
Indices 
(All Data) 
R1 = 
0.0542,  
wR2 = 
0.1030 
R1 = 
0.0632,  
wR2 = 
0.1442 
R1 = 
0.0332,  
wR2 = 
0.0751 
R1 = 0.543,  
wR2 = 
0.1112 
Largest 
Diff. 
Peak ; 
Hole (e Å-
3) 
0.39; -0.40 0.73 ; -0.69 1.11 ; -0.28 1.03 ; -0.40 
Flack 
Paramete
r 
-0.003(5) 0.018(6) 0.003(5) 0.018(7) 
CCDC  1492565 1492566 1492567 1492568 
 
The datasets for 2-(Rp), 2-(Sp), 3-(Rp) and 3-(Sp) were measured on an 
Agilent SuperNova diffractometer using an Atlas detector. The data 
collections were driven and processed and numerical absorption 
corrections based on gaussian integration over a multifaceted crystal 
model were applied using CrysAlisPro.[11] The structures were solved 
using ShelXS [12] and refined by a full-matrix least-squares procedure on 
F2 in ShelXL.[12] Figures and reports were produced using OLEX2.[13] The 
structures of 2-(Sp), 3-(Rp) and 3-(Sp) all contain two crystallographically-
independent molecules. All non-hydrogen atoms in all four structures were 
refined with anisotropic displacement parameters. In the structures of 2-
(Rp), 3-(Rp) and 3-(Sp) the hydrogen atoms bonded to nitrogen and oxygen 
atoms were located in the electron density and the positions refined, with 
the remaining hydrogen atoms being fixed as riding models. The Uiso of all 
hydrogen atoms were based on the Ueq of the parent atoms. In 2-(Sp) the 
hydrogen atoms bonded to N(3) and N(103) were located in the electron 
density and the positions and thermal parameters refined while the 
remaining hydrogen atoms were fixed as riding models with the Uiso of the 
hydrogen atoms being based on the Ueq of the parent atoms. 2-(Rp): The 
cyclopentadienyl ring C(15)-C(19) / C(15’)-C(19’) is disordered over two 
positions with the refined occupancy ratio being 0.591(19):0.409(19). The 
group C(20), C(21), O(21) / C(20’), C(21’), O(21’) is disordered over two 
positions with the occupancy ratio fixed due to symmetry constraints at 
0.5:0.5. 2-(Sp): The cyclopentadienyl ring C(15)-C(19) / C(15’)-C(19’) is 
disordered over two positions with the refined occupancy ratio being 
0.58(3)μ0.42(3). The group C(20), C(21), O(21) / C(0’), C(1’), O(1’) is 
disordered over two positions with the refined occupancy ratio being 
0.581(14)μ0.419(14). The group C(120), C(121), O(121) / C(20’), C(21’), 
O(21’) is disordered over two positions with the refined occupancy ratio 
being 0.525(11):0.475(11). 3-(Sp): The group C(120)-O(120)/C(20’)-O(20’) 
is disordered over two positions with the refined occupancy ratio being 
0.729(11):0.271(11). 
CCDC-1492565 – CCDC-1492568 contain the supplementary 
crystallographic data for this paper. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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